KVUE:NYSE
Kenvue Inc
$18.01
arrow_upward
+1.46%(+0.26) 1D
$18.01
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 14, 4:00:05 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KVUE...
Open
$17.92
High
$18.04
Low
$17.76
Mkt. cap
34.59B
Avg. vol.
24.20M
Volume
27.57M
Dividend
4.66%
Quarterly dividend
$0.21
Ex-dividend date
Sep 21, 2026
P/E ratio
20.88
52-wk high
$20.13
52-wk low
$14.02
EPS
$0.86
Beta
0.48
Shares outstanding
1.92B
No. of employees
22K
Open
$17.92
High
$18.04
Low
$17.76
Mkt. cap
34.59B
Avg. vol.
24.20M
Volume
27.57M
Dividend
4.66%
Quarterly dividend
$0.21
Ex-dividend date
Sep 21, 2026
P/E ratio
20.88
52-wk high
$20.13
52-wk low
$14.02
EPS
$0.86
Beta
0.48
Shares outstanding
1.92B
No. of employees
22K
News stories
From web sources and news partners
Reuters
·
1 day ago
EU approves Kimberly-Clark's $40 billion Kenvue acquisition
News Corp
·
1 day ago
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
Investing.com South Africa
·
1 day ago
Kimberly-Clark wins EU approval for Kenvue acquisition By Investing.com
Profile
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
About Kenvue Inc
CEOKirk Perry
Employees21.9K
Founded2022
HeadquartersSummit, New Jersey, United States
SectorPersonal care products
Websitekenvue.com